Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tardive Dyskinesia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Tardive Dyskinesia. Displaying page 1 of 1.
    EudraCT Number: 2011-004211-23 Sponsor Protocol Number: PI11-PR-KRYSTKOWIAK Start Date*: 2011-11-08
    Sponsor Name:CHU Amiens
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001685-35 Sponsor Protocol Number: ADT-2022-003 Start Date*: 2022-12-27
    Sponsor Name:Adeptio Pharmaceuticals Limited
    Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) HU (Ongoing) SK (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date*: 2022-09-02
    Sponsor Name:Adeptio Pharmaceuticals Ltd
    Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001302-27 Sponsor Protocol Number: N01142 Start Date*: 2005-06-10
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: An 8-week exploratory, double-blind, placebo controlled, randomized trial : Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administratio...
    Medical condition: Tardive dyskinesia usually occurs after prolonged exposure to antipsychotics and is characterized by abnormal choreiform, athetoic, choreathetoic or rhythmic involuntary movements. The localizatio...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10013928 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001890-15 Sponsor Protocol Number: SD-809-C-18 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002073-30 Sponsor Protocol Number: CAFQ056A2222 Start Date*: 2011-11-16
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: 12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson?s disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003135-19 Sponsor Protocol Number: SD-809-C-23 Start Date*: 2015-02-06
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019418-25 Sponsor Protocol Number: CAFQ056A2217 Start Date*: 2010-07-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias
    Medical condition: pazienti con malattia di Parkinson con discinesie indotte dalla L-dopa.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043118 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001891-73 Sponsor Protocol Number: SD-809-C-20 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-008712-98 Sponsor Protocol Number: CAFQ056A2208 Start Date*: 2009-05-18
    Sponsor Name:Novartis Pharma AG
    Full Title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013916 Dyskinesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001581-42 Sponsor Protocol Number: 17972A Start Date*: 2018-11-19
    Sponsor Name:H. Lunbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with sc...
    Medical condition: schizophrenia with persistent prominent negative symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006048-42 Sponsor Protocol Number: P04628 Start Date*: 2006-09-05
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects Wi...
    Medical condition: Patients with schizophrenia and schizoaffective disorders experiencing anti-psychotic-induced extra-pyramidal symptoms.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002780-30 Sponsor Protocol Number: 9515 Start Date*: 2022-12-01
    Sponsor Name:Aarhus University Hospital, The Research Clinic for Functional Disorders and Psychosomatics
    Full Title: Efficacy of patient education and duloxetine, alone and in combination, for patients with multiorgan bodily distress syndrome: a partial-factorial randomized controlled trial (the EDULOX-trial)
    Medical condition: Multiorgan Functional somatic disorders (FSD) / bodily disstress syndrome (BDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10041319 Somatization disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004546-15 Sponsor Protocol Number: 12-PP-12 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Nice
    Full Title: Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up
    Medical condition: severe behavioral disorders in mental retardation, autistic syndromes schizophrenia psychosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10033877 Paranoid type schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA